Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX – Get Free Report) traded up 8.1% during trading on Thursday . The company traded as high as $2.80 and last traded at $2.80. 6,604 shares were traded during mid-day trading, a decline of 65% from the average session volume of 18,945 shares. The stock had previously closed at $2.59.
Analyst Upgrades and Downgrades
Separately, Raymond James raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, May 22nd.
View Our Latest Research Report on EPRX
Eupraxia Pharmaceuticals Stock Down 7.1 %
Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($0.21) earnings per share for the quarter.
Hedge Funds Weigh In On Eupraxia Pharmaceuticals
A hedge fund recently bought a new stake in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC bought a new stake in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX – Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 13,000 shares of the company’s stock, valued at approximately $34,000.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.
Featured Articles
- Five stocks we like better than Eupraxia Pharmaceuticals
- Options Trading – Understanding Strike Price
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- What Are Trending Stocks? Trending Stocks Explained
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.